Novo Nordisk Inc. (NNI) Products

Tresiba^® (insulin degludec) injection is a long-acting human insulin analog indicated to improve glycemic control in patients 1 year of age and older with diabetes mellitus.

Levemir^® (insulin detemir) injection is a long-acting basal insulin indicated to improve glycemic control in adults and children with diabetes mellitus.

Fiasp^® (insulin aspart) injection is a rapid-acting human insulin analog indicated to improve glycemic control in adult and pediatric patients with diabetes mellitus.

NovoLog^® (insulin aspart) injection is a rapid acting human insulin analog indicated to improve glycemic control in adults and children with diabetes mellitus.

NovoLog^® Mix 70/30 (insulin aspart protamine and insulin aspart) injectable suspension is a premixed human insulin analog indicated to improve glycemic control in adult patients with diabetes mellitus.

Victoza^® (liraglutide) injection is a glucagon-like peptide-1 (GLP-1) receptor agonist indicated as an adjunct to diet and exercise to improve glycemic control in patients 10 years and older with type 2 diabetes mellitus and to reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke) in adults with type 2 diabetes mellitus and established cardiovascular disease.

Rybelsus^® (semaglutide) tablets is a glucagon-like peptide-1 (GLP-1) receptor agonist indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes.

Ozempic^® (semaglutide) injection is a glucagon-like peptide-1 (GLP-1) receptor agonist indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus, to reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction or non-fatal stroke) in adults with type 2 diabetes mellitus and established cardiovascular disease, and to reduce the risk of sustained estimated glomerular filtration rate decline, end-stage kidney disease, and cardiovascular death in adults with type 2 diabetes mellitus and chronic kidney disease.

Xultophy^® 100/3.6 (insulin degludec and liraglutide injection) is a combination of insulin degludec, a long-acting human insulin analog, and liraglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

GlucaGen^® (glucagon) for injection is a prescription medication for the treatment of severe hypoglycemia in pediatric and adult patients with diabetes mellitus and as a diagnostic aid for use during radiologic examinations to temporarily inhibit movement of the gastrointestinal tract in adult patients.

Zegalogue^® (dasiglucagon) injection is an antihypoglycemic agent indicated for the treatment of severe hypoglycemia in pediatric and adult patients with diabetes aged 6 years and above.

Novolin^® R (insulin human) injection is a short-acting human insulin indicated to improve glycemic control in adults and pediatric patients with diabetes mellitus.

Novolin^® N (isophane insulin human suspension) is an intermediate-acting human insulin indicated to improve glycemic control in adults and pediatric patients with diabetes mellitus.

Novolin^® 70/30 (human insulin isophane suspension and human insulin) injection is a premixed human insulin indicated to improve glycemic control in adults and pediatric patients with diabetes mellitus.

Wegovy^® (semaglutide) injection is a glucagon-like peptide-1 (GLP-1) receptor agonist indicated in combination with a reduced calorie diet and increased physical activity to reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction or non-fatal stroke) in adults with established cardiovascular disease and either obesity or overweight and to reduce excess body weight and maintain weight reduction long term in adults and pediatric patients aged 12 years and older with obesity and in adults with overweight in the presence of at least one weight-related comorbid condition.

Saxenda^® (liraglutide) injection is a glucagon-like peptide-1 (GLP-1) receptor agonist indicated in combination with a reduced calorie diet and increased physical activity to reduce excess body weight and maintain weight reduction long term in adults and pediatric patients aged 12 years and older with body weight greater than 60 kg and obesity and in adults with overweight in the presence of at least one weight-related comorbid condition.

Alhemo^® (concizumab-mtci) is a tissue factor pathway inhibitor (TFPI) antagonist indicated for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients 12 years of age and older with hemophilia A with FVIII inhibitors or hemophilia B with FIX inhibitors.

Esperoct^® [antihemophilic factor (recombinant), glycopegylated-exei] is a coagulation Factor VIII concentrate indicated for use in adults and children with hemophilia A for on-demand treatment and control of bleeding episodes, perioperative management of bleeding, and routine prophylaxis to reduce the frequency of bleeding episodes.

Novoeight^® (antihemophilic factor, recombinant) is indicated for use in adults and children with hemophilia A for on-demand treatment and control of bleeding episodes, perioperative management and routine prophylaxis to reduce the frequency of bleeding episodes.

NovoSeven^® RT (coagulation Factor VIIa, recombinant) is indicated for treatment of bleeding episodes and perioperative management in adults and children with hemophilia A or B with inhibitors, congenital Factor VII (FVII) deficiency, Glanzmann’s thrombosthenia with refractoriness to platelets (with or without antibodies to platelets), and treatment of bleeding episodes and perioperative management in adults with acquired hemophilia.

Rebinyn^® (Coagulation Factor IX (Recombinant), GlycoPEGylated), is a recombinant DNA-derived coagulation Factor IX concentrate indicated for use in adults and children with hemophilia B for on-demand treatment and control of bleeding episodes, perioperative management of bleeding, and routine prophylaxis to reduce the frequency of bleeding episodes.

Tretten^®, Coagulation Factor XIII A-Subunit (Recombinant) is indicated for routine prophylaxis of bleeding in patients with congenital factor XIII A-subunit deficiency.

Norditropin^® (somatropin) injection is a recombinant human growth indicated for treatment of pediatric patients with growth failure due to inadequate secretion of endogenous growth hormone (GH), short stature associated with Noonan Syndrome, short stature associated with Turner syndrome, short stature born small for gestational age (SGA) with no catch-up growth by age 2 to 4 years, Idiopathic Short Stature (ISS), and growth failure due to Prader-Willi Syndrome and replacement of endogenous GH in adults with growth hormone deficiency.

Sogroya^® (somapacitan-beco) injection is a human growth hormone analog indicated for replacement of endogenous growth hormone in adults with growth hormone deficiency.

Rivfloza^® (nedosiran) injection is an LDHA-directed small interfering RNA indicated to lower urinary oxalate levels in children 2 years of age and older and adults with primary hyperoxaluria type 1 (PH1) and relatively preserved kidney function.